DUBLIN--(BUSINESS WIRE)--The "Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline" report has been added to ResearchAndMarkets.com's offering.
"Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline" is a comprehensive, granular analysis of the 25,284 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into key therapy areas and indications. A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation.
Innovation in developing new products is the key element in growth in the pharmaceutical industry. The market is highly research-intensive, powered by high R&D investment, and it possesses a strong product pipeline to maintain growth and ensure long-term revenue generation. One of the methods companies use to gain more revenue is developing first-in-class products.
Though developing first-in-class products requires high investment in terms of time and money, it has proven to result in blockbuster drugs, when compared with me-too products. The perks of successful innovation are high, and without successful innovation companies would see a long decline in their growth.
All the therapy areas have shown growth in their pipeline size, of which the genetic disorders pipeline observed the highest change of nearly 130%. 80% of the rare diseases are genetic in origin, and progress in terms of understanding these diseases at the molecular and genome level is helping to create new medicines. Increasing patient population and high level of unmet needs in most of the diseased conditions are constantly driving the industry towards innovation.
Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily most years since 2002.
Small molecule products are leading the pipeline owing to their inherent nature of action and the cost of developing them. Small molecules have also proven their worth in generating revenue and are ranked top in terms of sales. Combination and multiple therapies are also a strategy to bring new drugs into market and maximize the return on investment. Currently oncology holds the highest number of multiple therapy drugs.
The Drug pipeline is also benchmarked against its size across each segment compared from Q1 2015 to Q3 2018. In addition, a detailed contextual analysis of the drivers of this pipeline in key therapy areas and an assessment of the level of first-in-class innovation is also provided.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Assessment of Pharmaceutical Industry Pipeline
4 Assessment of Innovation in the Pharmaceutical Industry Pipeline
5 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/323v44/pharmaceutical?w=4
